Neuropatia dolorosa associada ao HIV: onde estamos?

Pires, Karina Lebeis; Baranda, Marcelle Seraphim de Menezes; Brum, Talita Mota Almeida; Pessôa, Bruno; Pupe, Camila Castelo Branco; Nascimento, Osvaldo José Moreira do

doi:10.1590/0004-282X-ANP-2021-0079

Brasil

home Sumário navigate_before Anterior Atual Seguinte navigate_next

home Sumário

Article • Arq. Neuro-Psiquiatr. 80 (6) • Jun 2022 • https://doi.org/10.1590/0004-282X-ANP-2021-0079 linkcopiar

Neuropatia dolorosa associada ao HIV: onde estamos?

Autoria SCIMAGO INSTITUTIONS RANKINGS

RESUMO

Antecedentes: Após o advento da terapia antirretroviral combinada a infecção pelo vírus da imunodeficiência humana (HIV) deixou de ser uma doença devastadora, porém a neuropatia sensitiva consequente à permanência do vírus e ao efeito colateral do tratamento piora a morbidade desses pacientes.

Objetivo: Investigar a qualidade de vida de 64 pacientes com HIV, 24 com neuropatia dolorosa (grupo caso) e 40 sem neuropatia dolorosa (grupo controle). Avaliou-se também o impacto de outros fatores relacionados e não relacionados ao HIV na qualidade de vida.

Métodos: Para avaliação da neuropatia dolorosa foram utilizadas as escalas Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), Douleur Neuropathique 4 (DN4) e Escore de Comprometimento Neuropático (ECN). Para avaliação da qualidade de vida foi utilizada a escala Short Form Health Survey (SF-36). Fatores relacionados e não relacionados ao HIV foram obtidos através da anamnese e análise de prontuário.

Resultados: A qualidade de vida dos pacientes com dor neuropática foi pior em 6 dos 8 domínios da escala SF-36. O número de manifestações clínicas relacionadas ao HIV, tempo de carga viral detectável desde o diagnóstico, tempo de diagnóstico da infecção pelo vírus e tempo de uso de TARVC impactaram negativamente na qualidade de vida. Maior nível de CD4, da escolaridade e da renda familiar impactaram positivamente.

Conclusões: A neuropatia dolorosa relacionada ao HIV é fator de piora da qualidade de vida dos pacientes infectados por esse vírus devendo ser incluída na avaliação clínica desses pacientes.

Palavras-chave: Morbidade; HIV; Qualidade de Vida

Sociodemographic variables		HIV-positive patients				P-value of Fisher's exact test
		WITH painful neuropathy (n = 24)		NO painful neuropathy (n = 40)
		n	%	n	%
Sex	Female	13	54.2	22	55.0	1.000
Sex	Male	11	45.8	18	45.0	1.000
Age	31 - 39 years	5	20.8	14	35.0	0.396
	40 - 49 years	12	50.0	14	35.0
	50 - 55 years	7	29.2	12	30.0
Educational level	Up to 5 years of schooling	10	41.7	9	22.5	0.001
	6 - 9 years of schooling	7	29.2	29	72.5
	10 or more years of schooling	7	29.2	2	5.0
Income (minimum monthly wages)	1 - 2 mw	3	12.5	1	2.5	0.353
	2 - 3 mw	9	37.5	14	35.0
	3 - 4 mw	11	45.8	20	50.0
	> 4 mw	1	4.2	5	12.5

Variables not related to HIV		HIV+ patients				P-value of Fisher's exact test
		WITH painful neuropathy (n = 24)		NO painful neuropathy (n=40)
		n	%	n	%
Physical activity	Yes	5	20.8	16	40.0	0.170
Physical activity	No	19	79.2	24	60.0	0.170
BMI (kg/m²)	Up to 24.9 (normal)	7	29.2	25	62.5	0.003
	25 - 29.9 (overweight)	14	58.3	7	17.5
	30 or more (obesity)	3	12.5	8	20.0
History of depression	Yes	13	54.2	19	47.5	0.797
History of depression	No	11	45.8	21	52.5	0.797

Variables related to HIV		HIV-positive patients				P-value of Fisher's exact test
		WITH painful neuropathy (n = 24)		NO painful neuropathy (n=40)
		n	%	n	%
Length of time with the diagnosis of HIV infection	Up to 4 years	5	20.8	3	7.5	0.006
	5 - 9 years	5	20.8	21	52.5
	10 - 14 years	7	29.2	14	35.0
	15 or more	7	29.2	2	5.0
Number of ARV used	Up to 5	18	75.0	34	85.0	0.341
Number of ARV used	6 or more	6	25.0	6	15.0	0.341
Length of HAART use	Up to 9 years	11	45.8	26	65.0	0.192
Length of HAART use	10 or more	13	54.2	14	35.0	0.192
Number of hospitalizations	0	9	37.5	23	57.5	0.071
	1	6	25.0	12	30.0
	2 or more	9	37.5	5	12.5
Number of clinical manifestations related to HIV	0	3	12.5	14	35.0	0.130
	1	9	37.5	13	32.5
	2 or more	12	50.0	13	32.5
History of abandonment of HAART use	Yes	8	33.3	14	35.0	1.000
History of abandonment of HAART use	No	16	66.7	26	65.0	1.000
CD4 cell count	Up to 499	6	25.0	13	32.5	0.583
CD4 cell count	500 or more	18	75.0	27	67.5	0.583
Viral load	Undetectable	20	83.3	35	87.5	0.718
Viral load	Detectable	4	16.7	5	12.5	0.718
Time of VL detectable since diagnosis	1 year	8	33.3	26	65.0	0.051
	2 years	7	29.2	6	15.0
	3 years or more	9	37.5	8	20.0

Variables	HIV-positive groups	Descriptive statistics					Mann-Whitney test p-value
	HIV-positive groups	Average	Standard deviation	Minimum	Median	Maximum
	Age (years)	With painful neuropathy	46.7	5.8	35.0	47.5		55.0	0.296
No painful neuropathy	Age (years)	44.2	7.4	31.0	43.5	55.0			0.296
Years of study	With painful neuropathy	6.7	3.0	4.0	6.0	13.0	0.583
Years of study	No painful neuropathy	6.6	1.7	4.0	6.0	12.0	0.583
Income (MW)	With painful neuropathy	2.4	0.8	1.0	2.5	4.0	0.155
Income (MW)	No painful neuropathy	2.7	0.7	1.0	3.0	4.0	0.155
BMI (kg/m²)	With painful neuropathy	26.2	5.4	18.3	26.0	42.3	0.291
BMI (kg/m²)	No painful neuropathy	25.7	6.1	18.0	24.7	40.0	0.291
Infection duration (years)	With painful neuropathy	10.7	5.5	2.0	11.5	21.0	0.117
Infection duration (years)	No painful neuropathy	8.7	4.0	4.0	8.0	21.0	0.117
Number of ARV used	With painful neuropathy	4.5	1.5	3.0	4.0	9.0	0.522
Number of ARV used	No painful neuropathy	4.2	1.2	3.0	4.0	7.0	0.522
Duration of use of HAART (years)	With painful neuropathy	9.3	4.8	2.0	10.5	19.0	0.185
Duration of use of HAART (years)	No painful neuropathy	7.8	3.1	4.0	7.0	14.0	0.185
Number of clinical manifestations	With painful neuropathy	1.8	1.3	0.0	1.5	4.0	0.026
Number of clinical manifestations	No painful neuropathy	1.1	1.1	0.0	1.0	5.0	0.026
CD4	With painful neuropathy	670	345	14	682	1.257	0.321
CD4	No painful neuropathy	760	313	221	814	1.327	0.321
Detectable VL duration (years)	With painful neuropathy	2.9	2.7	1.0	2.0	12.0	0.019
Detectable VL duration (years)	No painful neuropathy	1.9	1.6	1.0	1.0	8.0	0.019

SF-36 domains	HIV-positive groups	Descriptive statistics					d = effect size	Mann-Whitney test p-value
SF-36 domains	HIV-positive groups	Average	Standard deviation	Minimum	Median	Maximum	d = effect size	Mann-Whitney test p-value
Functional capacity	With painful neuropathy	46.9	24.1	10.0	45.0	100.0	-2.9	0.008
Functional capacity	No painful neuropathy	95.4	9.7	60.0	100.0	100.0	-2.9	0.008
Physical aspects	With painful neuropathy	36.5	29.5	0.0	25.0	100.0	-2.1	< 0.001
Physical aspects	No painful neuropathy	91.3	24.4	0.0	100.0	100.0	-2.1	< 0.001
Pain	With painful neuropathy	40.2	12.4	20.0	41.0	52.0	-4.2	< 0.001
Pain	No painful neuropathy	93.5	12.9	51.0	100.0	100.0	-4.2	< 0.001
Emotional aspects	With painful neuropathy	24.9	32.4	0.0	25.0	100.0	-2.5	< 0.001
Emotional aspects	No painful neuropathy	90.5	22.0	0.0	100.0	100.0	-2.5	< 0.001
General health status	With painful neuropathy	52.5	23.8	27.0	42.0	92.0	-1.9	< 0.001
General health status	No painful neuropathy	87.3	14.2	40.0	89.5	100.0	-1.9	< 0.001
Vitality	With painful neuropathy	39.5	21.8	15.0	32.5	90.0	-1.5	< 0.001
Vitality	No painful neuropathy	75.9	26.6	0.0	87.5	100.0	-1.5	< 0.001
Social aspects	With painful neuropathy	39.0	26.5	12.0	25.0	100.0	-3.5	< 0.001
Social aspects	No painful neuropathy	98.1	6.7	75.0	100.0	100.0	-3.5	< 0.001
Mental health	With painful neuropathy	51.0	20.3	24.0	42.0	92.0	-1.8	< 0.001
Mental health	No painful neuropathy	84.3	16.9	32.0	91.0	100.0	-1.8	< 0.001

vertical_align_top file_download show_chart

more_horizclose
- image
- translate
- link
- article
- vertical_align_top
- file_download
- show_chart
- image
- translate
- link
- article

location_on

Academia Brasileira de Neurologia - ABNEURO R. Vergueiro, 1353 sl.1404 - Ed. Top Towers Offices Torre Norte, 04101-000 São Paulo SP Brazil, Tel.: +55 11 5084-9463 | +55 11 5083-3876 - São Paulo - SP - Brazil
E-mail: revista.arquivos@abneuro.org

rss_feed Acompanhe os números deste periódico no seu leitor de RSS

Acessibilidade / Reportar erro

[TFN1] Source: HUGG HIV/AIDS immunology outpatient clinic; mw: minimum monthly wages.